- BioAtla press release (NASDAQ:BCAB): Q2 GAAP EPS of -$0.44 in-line.
- Cash and cash equivalents as of June 30, 2024 were $61.7 million, compared to $111.5 million as of December 31, 2023.
- “We expect current cash and cash equivalents to fund planned operations through Q3 of 2025 which is sufficient to deliver clinical readouts in multiple indications, position our programs for one or more potentially registrational trials, and enhance our position in advancing strategic collaboration discussions.”
BioAtla GAAP EPS of -$0.44 in-line
